Virginia Espina

Protein microarrays: meeting analytical challenges for clinical applications.

Protein microarrays: molecular profiling technologies for clinical specimens.

Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays.

Molecular diagnostics.

Use of proteomic analysis to monitor responses to biological therapies.

Serum proteomics in cancer diagnosis and management.

Use of proteomic patterns to screen for gastrointestinal malignancies.

Clinical proteomics: revolutionizing disease detection and patient tailoring therapy.

Application of laser capture microdissection and protein microarray technologies in the molecular analysis of airway injury following pollution particle exposure.

Protein microarray detection strategies: focus on direct detection technologies.

Biomarkers of ovarian tumours.

Genomic and proteomic technologies for individualisation and improvement of cancer treatment.

Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays.

Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

Pathology of the future: molecular profiling for targeted therapy.

Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment.

Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.

Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays.

Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.

CSF proteome: a protein repository for potential biomarker identification.

An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement.

Manual exfoliation of fresh tissue obviates the need for frozen sections for molecular profiling.

A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer.

Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma.

[Development of the protein microarray technique and usefulness in individualized molecular tumor therapy]].

Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.

Laser capture microdissection.

Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis.

Physicochemically modified silicon as a substrate for protein microarrays.

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

Laser-capture microdissection.

Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.

The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.

A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.

Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy.

Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.

Laser capture microdissection technology.

Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.

Reverse phase protein microarrays for monitoring biological responses.

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.

Automated laser capture microdissection for tissue proteomics.

Reverse phase protein microarrays for theranostics and patient-tailored therapy.

Molecular network analysis using reverse phase protein microarrays for patient tailored therapy.

A portrait of tissue phosphoprotein stability in the clinical tissue procurement process.

Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.

Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers.

Reverse-phase protein microarrays for theranostics and patient tailored therapy.

Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment.

Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer.

Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells.

Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response.

Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.

The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease.

Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH.

Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival.

Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles.

Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery.

Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability.

Tumorigenic and metastatic activity of human thyroid cancer stem cells.

Reverse phase protein microarrays advance to use in clinical trials.

The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease.

Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL.

Reverse-phase phosphoproteome analysis of signaling pathways induced by Rift valley fever virus in human small airway epithelial cells.

What is the malignant nature of human ductal carcinoma in situ?

A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum.

Breast cancer stem cells: a new target for therapy.

Reverse phase protein microarrays: fluorometric and colorimetric detection.

One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens.

Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology.

Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers.

Reduction of preanalytical variability in specimen procurement for molecular profiling.

Laser capture microdissection: Arcturus(XT) infrared capture and UV cutting methods.

Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples.

Guidelines for the use and interpretation of assays for monitoring autophagy.

Laser capture microdissection for protein and NanoString RNA analysis.

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Attacking breast cancer at the preinvasion stage by targeting autophagy.

Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.

Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress.

Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways.

Application of Analyte Harvesting Nanoparticle Technology to the Measurement of Urinary HGH in Healthy Individuals.

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.

Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations.

Ductal carcinoma in situ: challenges, opportunities, and uncharted waters.

Stratification of clear cell renal cell carcinoma by signaling pathway analysis.

Protein pathway analysis in Clinical Proteomics using protein microarrays.

Protein painting reveals solvent-excluded drug targets hidden within native protein-protein interfaces.

Inhibition of Histone Deacetylase 4 Increases Cytotoxicity of Docetaxel in Gastric Cancer Cells.

Whole proteome analysis of mouse lymph nodes in cutaneous anthrax.

Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine.